FDA Rejected Paxil Label Changes, GSK Says In Suicide Trial
GlaxoSmithKline told an Illinois federal jury Wednesday that the U.S. Food and Drug Administration four times rejected a label change that would have alerted doctors of the increased risk of suicide...To view the full article, register now.
Already a subscriber? Click here to view full article